Literature DB >> 22904042

Pyridine nucleotide regulation of cardiac intermediary metabolism.

John R Ussher1, Jagdip S Jaswal, Gary D Lopaschuk.   

Abstract

The pyridine nucleotides NAD(+) and NADP(+) play a pivotal role in regulating intermediary metabolism in the heart. The intracellular NAD(+)/NADH ratio controls flux through various dehydrogenase enzymes involved in both anaerobic and aerobic metabolism and also regulates posttranslational protein modification. The intracellular NADP(+)/NADPH ratio controls flux through the pentose phosphate pathway (PPP) and the polyol pathway, while also regulating ion channel function and oxidative stress. Not only does the NAD(+)/NADH ratio regulate the rates of ATP production, it can also modify energy substrate preference. For instance, in many forms of heart disease a greater contribution from fatty acids for oxidative energy metabolism increases fatty acid β-oxidation-derived NADH, which can activate pyruvate dehydrogenase (PDH) kinase isoforms that inhibit PDH and subsequent glucose oxidation. As such, novel therapies that overcome fatty acid β-oxidation-induced inhibition of PDH improve cardiac efficiency and subsequent function during ischemia/reperfusion and in heart failure. Furthermore, recent studies have implicated a pivotal role for increased PPP-derived NADPH in mediating oxidative stress observed in heart failure. In this article, we review the multiple actions of NAD(+)/NADH and NADP(+)/NADPH in regulating intermediary metabolism in the heart. A better understanding of the roles of NAD(+)/NADH and NADP(+)/NADPH in cellular physiology and pathology could potentially be used to exploit pyridine nucleotide modification in the treatment of a number of different forms of heart disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904042     DOI: 10.1161/CIRCRESAHA.111.246371

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  40 in total

Review 1.  Pyridine Dinucleotides from Molecules to Man.

Authors:  Joshua P Fessel; William M Oldham
Journal:  Antioxid Redox Signal       Date:  2017-07-25       Impact factor: 8.401

Review 2.  Cardiac metabolism in heart failure: implications beyond ATP production.

Authors:  Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 3.  Metabolism in cardiomyopathy: every substrate matters.

Authors:  Julia Ritterhoff; Rong Tian
Journal:  Cardiovasc Res       Date:  2017-03-15       Impact factor: 10.787

Review 4.  Regulation of ion channels by pyridine nucleotides.

Authors:  Peter J Kilfoil; Srinivas M Tipparaju; Oleg A Barski; Aruni Bhatnagar
Journal:  Circ Res       Date:  2013-02-15       Impact factor: 17.367

5.  NAD(H) in mitochondrial energy transduction: implications for health and disease.

Authors:  Matthew A Walker; Rong Tian
Journal:  Curr Opin Physiol       Date:  2018-04-11

Review 6.  Recent advances in mitochondrial research.

Authors:  Bradford G Hill
Journal:  Circ Res       Date:  2013-12-06       Impact factor: 17.367

7.  Raising NAD in Heart Failure: Time to Translate?

Authors:  Matthew A Walker; Rong Tian
Journal:  Circulation       Date:  2018-05-22       Impact factor: 29.690

Review 8.  Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.

Authors:  Andrew N Carley; Heinrich Taegtmeyer; E Douglas Lewandowski
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

9.  Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose.

Authors:  Niraj M Bhatt; Miguel A Aon; Carlo G Tocchetti; Xiaoxu Shen; Swati Dey; Genaro Ramirez-Correa; Brian O'Rourke; Wei Dong Gao; Sonia Cortassa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

10.  NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation.

Authors:  Jing-Si Zhou; Zhou Zhu; Feng Wu; Ying Zhou; Rui Sheng; Jun-Chao Wu; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.